IMPORTANCE: Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and overall survival of 8.0 and 11.7 months, respectively. New treatments offering improved survival outcomes are therefore needed. OBJECTIVE: To evaluate the association between progression-free survival and the addition of nanoparticle albumin-bound (nab)-paclitaxel to gemcitabine-cisplatin for the treatment of patients with advanced biliary tract cancer. DESIGN, SETTING, AND PARTICIPANTS: This open-label, single-arm, phase 2 clinical trial conducted at the University of Texas MD Anderson Cancer Center and the Mayo Clinic in Phoenix, Arizona, enrolled 62 patients with advanced biliary tract cancers between April 14, 2015, and April 24, 2017. INTERVENTIONS: Patients initially received gemcitabine, 1000 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel, 125 mg/m2, on days 1 and 8 of 21-day cycles. Owing to hematologic adverse events among the first 32 patients enrolled, these starting doses were reduced to 800, 25, and 100 mg/m2, respectively, for the remaining 28 patients. MAIN OUTCOMES AND MEASURES: The primary trial end point was investigator-assessed progression-free survival in the intention-to-treat population. RESULTS: Of 60 patients who started treatment, the mean (SD) age was 58.4 (11.0) years, 38 (63%) had intrahepatic cholangiocarcinoma, 9 (15%) had extrahepatic cholangiocarcinoma, 13 (22%) had gallbladder cancer, 47 (78%) had metastatic disease, and 13 (22%) had locally advanced disease. Median follow-up was 12.2 (95% CI, 9.4-19.4) months, and median progression-free survival was 11.8 (95% CI, 6.0 to 15.6) months. The partial response rate was 45%, and the disease control rate was 84%. Median overall survival was 19.2 months (95% CI, 13.2 months to not estimable). Patients in the safety population (n = 57) received a median of 6 (interquartile range, 3-11) cycles of treatment; 26 patients (46%) remained on their starting dose throughout the trial. Grade 3 or higher adverse events occurred in 58% of patients, and 9 patients (16%) withdrew owing to adverse events. Neutropenia was the most common grade 3 or higher adverse event, occurring in 19 patients (33%) overall. Post hoc analyses showed that treatment efficacy was not significantly associated with starting dose, tumor type, or disease status and that tolerability was improved with reduced- vs high-dose treatment. CONCLUSIONS AND RELEVANCE: Treatment with nab-paclitaxel plus gemcitabine-cisplatin prolonged median progression-free survival and overall survival vs those reported for historical controls treated with gemcitabine-cisplatin alone. These findings will be tested in a phase 3 randomized clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02392637.
IMPORTANCE: Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and overall survival of 8.0 and 11.7 months, respectively. New treatments offering improved survival outcomes are therefore needed. OBJECTIVE: To evaluate the association between progression-free survival and the addition of nanoparticle albumin-bound (nab)-paclitaxel to gemcitabine-cisplatin for the treatment of patients with advanced biliary tract cancer. DESIGN, SETTING, AND PARTICIPANTS: This open-label, single-arm, phase 2 clinical trial conducted at the University of Texas MD Anderson Cancer Center and the Mayo Clinic in Phoenix, Arizona, enrolled 62 patients with advanced biliary tract cancers between April 14, 2015, and April 24, 2017. INTERVENTIONS: Patients initially received gemcitabine, 1000 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel, 125 mg/m2, on days 1 and 8 of 21-day cycles. Owing to hematologic adverse events among the first 32 patients enrolled, these starting doses were reduced to 800, 25, and 100 mg/m2, respectively, for the remaining 28 patients. MAIN OUTCOMES AND MEASURES: The primary trial end point was investigator-assessed progression-free survival in the intention-to-treat population. RESULTS: Of 60 patients who started treatment, the mean (SD) age was 58.4 (11.0) years, 38 (63%) had intrahepatic cholangiocarcinoma, 9 (15%) had extrahepatic cholangiocarcinoma, 13 (22%) had gallbladder cancer, 47 (78%) had metastatic disease, and 13 (22%) had locally advanced disease. Median follow-up was 12.2 (95% CI, 9.4-19.4) months, and median progression-free survival was 11.8 (95% CI, 6.0 to 15.6) months. The partial response rate was 45%, and the disease control rate was 84%. Median overall survival was 19.2 months (95% CI, 13.2 months to not estimable). Patients in the safety population (n = 57) received a median of 6 (interquartile range, 3-11) cycles of treatment; 26 patients (46%) remained on their starting dose throughout the trial. Grade 3 or higher adverse events occurred in 58% of patients, and 9 patients (16%) withdrew owing to adverse events. Neutropenia was the most common grade 3 or higher adverse event, occurring in 19 patients (33%) overall. Post hoc analyses showed that treatment efficacy was not significantly associated with starting dose, tumor type, or disease status and that tolerability was improved with reduced- vs high-dose treatment. CONCLUSIONS AND RELEVANCE: Treatment with nab-paclitaxel plus gemcitabine-cisplatin prolonged median progression-free survival and overall survival vs those reported for historical controls treated with gemcitabine-cisplatin alone. These findings will be tested in a phase 3 randomized clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02392637.
Authors: E Gabriela Chiorean; Rashmi Ramasubbaiah; Menggang Yu; Joel Picus; Jose A Bufill; Yan Tong; Nicki Coleman; Erica L Johnston; Colleen Currie; Patrick J Loehrer Journal: Oncologist Date: 2011-12-30
Authors: P Papakostas; C Kouroussis; N Androulakis; G Samelis; G Aravantinos; K Kalbakis; E Sarra; J Souglakos; S Kakolyris; V Georgoulias Journal: Eur J Cancer Date: 2001-10 Impact factor: 9.162
Authors: Thomas J Smith; Kari Bohlke; Gary H Lyman; Kenneth R Carson; Jeffrey Crawford; Scott J Cross; John M Goldberg; James L Khatcheressian; Natasha B Leighl; Cheryl L Perkins; George Somlo; James L Wade; Antoinette J Wozniak; James O Armitage Journal: J Clin Oncol Date: 2015-07-13 Impact factor: 44.544
Authors: R Alvarez; M Musteanu; E Garcia-Garcia; P P Lopez-Casas; D Megias; C Guerra; M Muñoz; Y Quijano; A Cubillo; J Rodriguez-Pascual; C Plaza; E de Vicente; S Prados; S Tabernero; M Barbacid; F Lopez-Rios; M Hidalgo Journal: Br J Cancer Date: 2013-08-01 Impact factor: 7.640
Authors: J W Valle; H Wasan; P Johnson; E Jones; L Dixon; R Swindell; S Baka; A Maraveyas; P Corrie; S Falk; S Gollins; F Lofts; L Evans; T Meyer; A Anthoney; T Iveson; M Highley; R Osborne; J Bridgewater Journal: Br J Cancer Date: 2009-08-18 Impact factor: 7.640
Authors: Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores Journal: Nat Rev Gastroenterol Hepatol Date: 2020-06-30 Impact factor: 46.802
Authors: Avani Athauda; Caroline Fong; David K Lau; Milind Javle; Ghassan K Abou-Alfa; Chigusa Morizane; Keith Steward; Ian Chau Journal: Cancer Treat Rev Date: 2020-03-12 Impact factor: 12.111
Authors: Alexander J Rossi; Tahsin M Khan; Allen J Luna; Andrea Cercek; William R Jarnagin; Jonathan M Hernandez Journal: Ann Surg Oncol Date: 2021-06-11 Impact factor: 5.344
Authors: Gayle S Jameson; Erkut Borazanci; Hani M Babiker; Elizabeth Poplin; Anna A Niewiarowska; Michael S Gordon; Michael T Barrett; Adam Rosenthal; Amy Stoll-D'Astice; John Crowley; Lynn Shemanski; Ron L Korn; Karen Ansaldo; Leticia Lebron; Ramesh K Ramanathan; Daniel D Von Hoff Journal: JAMA Oncol Date: 2019-10-03 Impact factor: 31.777